title: Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
abstract: BACKGROUND
  P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.
  
  
  METHODS
  Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian-Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.
  
  
  RESULTS
  A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.
  
  
  CONCLUSIONS
  Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies.
authors.affiliation: Department of Gynaecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: de Graeff
authors.forename: A P G
authors.initials: AP
authors.lastname: Crijns
authors.forename: S
authors.initials: S
authors.lastname: de Jong
authors.forename: M
authors.initials: M
authors.lastname: Boezen
authors.forename: W J
authors.initials: WJ
authors.lastname: Post
authors.forename: E G E
authors.initials: EG
authors.lastname: de Vries
authors.forename: A G J
authors.initials: AG
authors.lastname: van der Zee
authors.forename: G H
authors.initials: GH
authors.lastname: de Bock
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000201:enzymology / Q000378:metabolism*; D011379:Prognosis; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; C495901:TP53 protein, human